HematologyNews.net

Hematology Xagena

Xagena Mappa
Medical Meeting
Reumabase.it
Gastrobase.it

Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies indicated that leukemias harboring these mutations may respond to ALK inhibitors such as Crizot ...


Positive top-line results of the Kids B-LONG phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix [ Coagulation Factor IX ( Recombinant ), Fc Fusion Protein ] in ...


Eight of 14 patients in the first trial of the University of Pennsylvania’s personalized cellular therapy for chronic lymphocytic leukemia ( CLL ) responded to the therapy, with some complete remissio ...


A planned interim analysis has shown that the phase 3 head-to-head clinical trial ENDEAVOR evaluating Carfilzomib ( Kyprolis ) for injection in combination with low-dose Dexamethasone versus Bortezomi ...


The FDA ( Food and Drug Administration ) has approved Farydak ( Panobinostat, previously known as LBH589 ) capsules in combination with Bortezomib ( Velcade ) and Dexamethasone for the treatment of pa ...


Vitamin D is increasingly recognized for its roles in non-skeletal disorders. Patients with sickle cell disease ( SCD ) have a high prevalence of vitamin D deficiency but data are limited with respect ...


The FDA ( Food and Drug Administration ) has granted approval of Blincyto ( Blinatumomab ) for the treatment of patients with Philadelphia chromosome-negative ( Ph- ) relapsed or refractory B-cell pre ...


Data from the largest clinical trial of myelofibrosis patients treated with Ruxolitinib ( Jakavi ) were presented at 56th Annual Meeting of the American Society of Hematology ( ASH ) in San Francisco ...


The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. Researchers hypothesized that such mutations would be detect ...


Final data from a phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic events ( VTE ) in patients treated with ISIS-FXI Rx undergoing total knee replacement surgery, o ...


The results from the STRATUS trial ( MM-010 ), a single-arm phase IIIb study of Pomalidomide ( Imnovid, Pomalyst ) plus low-dose Dexamethasone in patients with relapsed and refractory multiple myeloma ...


Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, has achieved an overall response rate of 66%, as assessed by International Harmonization Project response criteria ( n=19/29: 95% CI, 46-82 ), in tran ...


Positive results from a cohort of patients in its ongoing phase 1b trial ( CheckMate-039 ) which evaluated PD-1 immune checkpoint inhibitor, Nivolumab ( Opdivo), in patients with relapsed or refractor ...


Venous and arterial thromboses have been regarded for many years as two different diseases requiring anticoagulant or antiplatelet treatment, respectively. Platelets have a role in venous thromboe ...


Chronic ophthalmological complications of SCD include proliferative sickle retinopathy ( PSR ) and vitreous hemorrhage. They occur in up to 50% of individuals with SCD, and are found more frequently ...